We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
J&J is collaborating with HHS’ Biomedical Advanced Research and Development Authority and the National Institute for Allergy and Infectious Diseases. Read More
Johnson and Johnson (J&J) yesterday became the fourth drugmaker to begin a large-scale phase 3 trial of a COVID-19 vaccine candidate — and it will be the largest late-stage trial of a COVID-19 vaccine to date. Read More
Chinese drugmakers Sinovac Biotech and CanSino Biologics yesterday began separate late-stage trials of their COVID-19 vaccines in Turkey and Pakistan. Read More
New York biotech Codagenix announced Tuesday that the Serum Institute of India has begun manufacturing its intranasal COVID-19 vaccine candidate, CDX-005. Read More
The National Institutes of Health (NIH) yesterday announced the expansion of two late-stage trials of convalescent plasma in the wake of the FDA’s Emergency Use Authorization (EUA) for the investigational COVID-19 treatment. Read More
Gary Kobinger, the leader of the Canadian research team that developed a highly effective Ebola vaccine, has stepped down from Canada’s COVID-19 vaccine task force, calling for greater transparency from the group. Read More
The FDA’s planned guidance on Emergency Use Authorization (EUA) of COVID-19 vaccines may be released as soon as this week and could include standards making an EUA unlikely before the Nov. 3 presidential election. Read More
Merck said its blockbuster cancer drug Keytruda (pembrolizumab) doubled patients’ five-year survival rate compared to chemotherapy in a late-stage trial as a first-line treatment for metastatic nonsmall-cell lung cancer (NSCLC). Read More